Regulatory & Legal

An expanded partnership aims to create next-gen cancer therapies by combining bispecific antibodies with two distinct drugs to overcome tumor resistance.

With a new board chair, regulatory backing, and an AI platform, GC Therapeutics is targeting MS and diabetes with next-generation cell therapies.

The biotech firm now expects Phase 2 results in Q3 2026, accelerating hope for new CNS treatments and signaling strong operational momentum to investors.

Thousands of parents will explore a burgeoning marketplace of school options in Las Vegas, from public charters to private academies, amid new state policies.

Surging NYC energy bills have homeowners facing a tough choice. Learn the key signs that your aging HVAC system needs replacement, not another costly repair.

Facing a Nasdaq delisting notice, Chinese office provider Ucommune plans drastic measures amid dire financials and a saturated real estate market.

Backed by CRISPR pioneers and $16M, a new biotech aims to make personalized gene therapies a scalable reality for millions with rare genetic disorders.

Kezar Life Sciences faces a critical FDA meeting for its novel liver disease drug, a decision that could bring hope to patients and define the company's future.

Amid a major corporate restructure, Atos partners with the World DanceSport Federation, betting on tech to transform the ballroom and secure its market lead.

Sanuwave Health posts record revenue, defying industry-wide turmoil as reimbursement cuts reshape the advanced wound care market. How did they do it?

A 2.9 MEUR deal for GomSpace to design lunar spacecraft for a major North American firm signals a new era for small satellites in deep space exploration.

As 2026 begins, the crypto market sees a split personality: a wild memecoin surge alongside a steady, tech-driven recovery in the AI sector.

A 70-year-old infrastructure giant launches a new power company, aiming to redefine grid projects with an integrated, civil-first approach.

Operational failures at a key Texas plant and a sudden drop in chlorine demand force chemical giant Olin Corp. to drastically cut its Q4 earnings forecast.

The first system pairing a one-year implantable glucose monitor with an automated insulin pump is now available, promising to transform daily life for people with diabetes.

With 155 illnesses and hundreds of products recalled, a widespread Salmonella outbreak linked to pistachios has put Canada's food safety system to the test.

The 2025-2030 Dietary Guidelines praise eggs as a top protein, but experts question the new, broader focus on animal products and increased protein intake.

A historic $1 million estate gift launches Pink Fund's 20th anniversary, securing its future and highlighting the hidden financial burdens of breast cancer.

The American Library Association marks its sesquicentennial with a year of celebration, highlighting its legacy and confronting a modern surge in censorship.

MiNK Therapeutics and UW–Madison launch a trial for an 'off-the-shelf' cell therapy, aiming to prevent deadly Graft-Versus-Host Disease (GvHD).